Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Tecentriq concentrate for solution for infusion placebo 0mg, Tecentriq 840 mg concentrate for solution for infusion
Roche Registration Limited
High-risk muscle-invasive bladder cancer
1 trial -
Tiragolumab Placebo, Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab, Tecentriq Placebo
Roche Registration Limited
Unresectable Esophageal Squamous Cell Carcinoma
1 trial -
Tiragolumab, Placebo Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion
Roche Registration Limited
Non-small cell lung cancer (NSCLC)
1 trial -
Venclexta, Venclyxto, Levact 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Venclexta, Venclyxto, Fludarabinphosphat "Ebewe", koncentrat til injektions-/infusionsvæske, opløsning, Venclexta, Venclyxto, Fludarabin Ebewe 25 mg/ml injektio-/infuusiokonsentraatti, liuosta varten, Fludarabin Sandoz 25 mg/ml injekčný alebo infúzny koncentrát, MabThera 500 mg concentrate for solution for infusion, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, Bendamustin cell pharm® 2,5
Roche Registration Limited
Chronic Lymphocytic Leukemia (CLL)
1 trial -
Verzenios 150 mg film-coated tablets, Kisqali 200 mg film-coated tablets, Faslodex 250 mg solution for injection., IBRANCE 75 mg film-coated tablets, LEUPRORELIN , Verzenios 100 mg film-coated tablets, RO7197597, RIBOCICLIB, IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, Verzenios 50 mg film-coated tablets
Roche Registration Limited
Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
1 trial -
Vincristine placebo, VINCRISTINE , Polivy 140 mg powder for concentrate for solution for infusion., MabThera 500 mg concentrate for solution for infusion
Roche Registration Limited
Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
1 trial -
XALKORI 200 mg hard capsules, Alecensa 150 mg hard capsules, XALKORI 200 mg hard capsules, Alectinib (Alecensa), XALKORI 250 mg hard capsules, XALKORI 250 mg hard capsules
Roche Registration Limited
Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
1 trial -
XALKORI 250 mg hard capsules, XALKORI 250 mg hard capsules, XALKORI 200 mg hard capsules, Rozlytrek, Rozlytrek, Rozlytrek, Rozlytrek 100 mg hard capsules, Rozlytrek, Rozlytrek 200 mg hard capsules, Rozlytrek, Rozlytrek, Rozlytrek, Rozlytrek, XALKORI 200 mg hard capsules, Rozlytrek, Rozlytrek
Roche Registration Limited
Non-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene rearrangements
1 trial -
A 3-Arm, Randomized, Blinded, Active-Controlled, Phase II Study of RO7121661, a PD1-TIM3 Bispecific Antibody and RO7247669, a PD1-LAG3 Bispecific Antibody, Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Roche Registration Limited
Advanced or metastatic squamous cell carcinoma of the esophagus
1 trial -
A Phase II Multicenter, Open-Label Study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Pediatric Patients with Duchenne Muscular Dystrophy (SHIELD DMD)
Roche Registration Limited
Duchenne Muscular Dystrophy (DMD)
1 trial -
A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma
Roche Registration Limited
Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
1 trial -
A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Roche Registration Limited
Previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)
1 trial -
A Phase II, Single-Arm, Open-Label Study Evaluating the Safety and Pharmacokinetics of the Intravenous Fixed‑Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants with Locally Advanced, Recurrent or Metastatic Solid Tumors
Roche Registration Limited
Solid Tumors
1 trial -
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis
Roche Registration Limited
Relapsing Multiple Sclerosis
1 trial -
A Randomized, Open-Label, Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Roche Registration Limited
Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
1 trial -
ALECTINIB
Roche Registration Limited
ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment available
1 trial -
Abraxane 5 mg/ml powder for dispersion for infusion., Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, RoActemra 20 mg/mL concentrate for solution for infusion, Gemcitabin AqVida 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Gemcitabin Kabi 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Avastin 25 mg/ml concentrate for solution for infusion., ATEZOLIZUMAB, Tiragolumab
Roche Registration Limited
Pancreatic ductal adenocarcinoma (PDAC)
1 trial -
An Open-Label, Multi-Center, Phase Ib/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
Roche Registration Limited
Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)
1 trial -
Avastin 25 mg/ml concentrate for solution for infusion., Lynparza 150 mg film-coated tablets, Cotellic 20 mg film-coated tablets, Ipatasertib, Cotellic, Cotellic, INAVOLISIB, Sindaxel 6 mg/ml concentrat pentru soluţie perfuzabilă, Verzenios 50 mg film-coated tablets, Cotellic, Lynparza 100 mg film-coated tablets, Kadcyla 160 mg powder for concentrate for solution for infusion., LETRO-cell® 2,5 mg Filmtabletten, INAVOLISIB, Verzenios 100 mg film-coated tablets, INAVOLISIB, Lynparza 150 mg film-coated tablets
Roche Registration Limited
Persistent or Recurrent Rare Epithelial Ovarian Tumors
1 trial -
Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Camonsertib, Trajenta 5 mg film-coated tablets
Roche Registration Limited
Metastatic non-small cell lung cancer (NSCLC)
1 trial -
BCG-MEDAC, poudre et solvant pour suspension intravésicale, PD1IL2v iMAb
Roche Registration Limited
BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)
1 trial -
Budenofalk 3mg magensaftresistente Hartkapseln, ALIMTA 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion., CISPLATINE ACCORD 1 mg/ml, solution à diluer pour perfusion, Carboplatin-GRY® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infu
Roche Registration Limited
Untreated Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial -
Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, Alectinib (Alecensa), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Pemetrexed Pfizer 25 mg/ml concent
Roche Registration Limited
Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Cevostamab, RoActemra 20 mg/mL concentrate for solution for infusion
Roche Registration Limited
Relapsed/Refractory Multiple Myeloma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources